Restless legs syndrome (RLS) is a neurological disorder characterized by uncomfortable or unpleasant sensations in the legs and an irrepressible urge to move them. The symptoms of RLS often worsen during periods of rest or inactivity such as lying down or sitting. Some of the major advantages of RLS treatment include relief from unpleasant sensations and improved sleep quality. There is a growing need for effective RLS treatment options as the condition can negatively impact quality of life if left untreated.
The Restless Legs Syndrome Treatment Market is estimated to be valued at US$ 2.5 Bn in 2024 and is expected to exhibit a CAGR of 5.7% over the forecast period of 2024-2031.
Increasing awareness among patients and healthcare providers about RLS and availability of various treatment alternatives are some of the key factors fueling market growth.
Key Takeaways
Key players operating in the restless legs syndrome treatment market are GlaxoSmithKline, Teva Pharmaceuticals, Boehringer Ingelheim, Pfizer Inc., and UCB Pharma. GlaxoSmithKline dominated the market in 2021 with its popular drug Horizant used for the treatment of moderate-to-severe primary RLS.
In terms of opportunities, there is latent demand for biomarkers to enable early and accurate diagnosis of RLS. This presents an avenue for companies to invest in development of diagnostic biomarkers which can help identify high-risk patients.
Geographically, North America holds the largest share of the global RLS treatment market owing to high awareness levels, diagnosis rates, and adoption of treatment therapies in the region. However, the Asia Pacific market is expected to expand at the fastest CAGR during the forecast period driven by growing healthcare expenditure and expanding access to treatment options.
Market Drivers
One of the major drivers of the restless legs syndrome treatment market is the rising prevalence of RLS globally. It is estimated that around 10% of the adult population suffers from RLS worldwide. Increasing sedentary lifestyle and obesity rates are some of the key factors contributing to the rising prevalence.
Market Restrains
High costs associated with RLS treatment drugs pose a major challenge to market growth. Some of the branded RLS medication options cost upwards of $1000 per month creating affordability issues for patients. This has led to lower adoption rates in developing regions with budget constraints.
Segment Analysis
The Restless Legs Syndrome Treatment market is segmented into drug type, distribution channel and geography. By drug type, the dopamine agonists segment holds the largest market share as these drugs are considered a first-line treatment for RLS. Pregabalin is another dominating sub segment due to its efficacy and fewer side effects. By distribution channel, hospitals pharmacies are the prominent segment as it is most convenient for patients to obtain prescription-based RLS drugs.
Global Analysis
North America dominates the Restless Legs Syndrome Treatment market with the largest revenue share. This is attributed to growing prevalence of RLS, strong healthcare infrastructure and availability of advanced treatment options in the region. Asia Pacific is expected to witness the highest growth during the forecast period owing to increasing patient awareness, rising healthcare spending and presence of generic drug manufacturers. China, Japan and India are emerging markets for RLS drugs in Asia Pacific. Germany, UK and France collectively form a major revenue pocket in Europe due to rising government support for early diagnosis and treatment of neurological disorders.
Get more insights on this topic: https://www.dailyprbulletin.com/restless-legs-syndrome-treatment-market-is-trending-by-growing-patient-awareness/
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)
What Are The Key Data Covered In This Restless Legs Syndrome Treatment Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Restless Legs Syndrome Treatment Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Restless Legs Syndrome Treatment Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Restless Legs Syndrome Treatment Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Restless Legs Syndrome Treatment Market vendors
FAQ’s
Q.1 What are the main factors influencing the Restless Legs Syndrome Treatment Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Restless Legs Syndrome Treatment Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Restless Legs Syndrome Treatment Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it